Chiron Corp. has named its senior management team that willdirect key operations following last week's merger with CetusCorp. Michael S. Ostrach, formerly Cetus' general counsel, willhead Chiron Technologies, a new business unit. Dr. William G.Gerber, who had been head of Cetus' PCR group, will leadChiron Diagnostics. Frank P. McCormick, Ph.D., former head ofresearch and development at Cetus, will head therapeutics andbiological research. Pablo D.T. Valenzuela, Ph.D., who had beenhead of research at Chiron, will head diagnostic research andprocess development. Chiron (NASDAQ:CHIR) is located inEmeryville, Calif.
BioCryst Inc. of Birmingham, Ala., has reincorporated fromNevada to Delaware with the new name BioCrystPharmaceuticals Inc. As part of the reorganization, JohnPappajohn of Equity Dynamics and Lindsay Rosenwald of TheCastle Group have been named directors, while David Hale,president of Gensia Pharmaceuticals Inc., will be leaving theboard. Hale will remain an adviser for the privately heldrational drug design company.
U.S. Bioscience Inc. of West Conshohocken, Pa., has promotedBarbara J. Scheffler to senior vice president of clinicaloperations and regulatory affairs. She had been vice presidentof clinical operations. Also promoted were John S. McBride tovice president of business development from senior director,and Robert L. Myers to vice president of information sciences,from director. U.S. Bioscience (AMEX:UBS) develops drugs toincrease the survival and quality of life for patients withcancer and allied diseases.
Agouron Pharmaceuticals Inc. of San Diego has appointed GaryE. Friedman vice president and general counsel. Friedman wasa principal in the San Diego law firm of Friedman, Jay andCramer, which has served the company as outside counsel.Agouron (NASDAQ:AGPH) focuses on the design of syntheticdrugs based upon the molecular structures of proteins.
Cytel Corp. of San Diego said Kenneth J. Collins has resigned asexecutive vice president of finance and administration, chieffinancial officer and director. He will rejoin Synergen Inc. asvice president of finance and administration, a position he heldprior to joining Cytel in August. Cytel (NASDAQ:CYTL) focuseson the discovery and design of drugs to treat immune systemdisorders and inflammatory diseases.
Repligen Corp. of Cambridge, Mass., has named Daniel P. Witt,Ph.D., vice president of technology acquisition. Witt had beendirector of new technology assessment. Repligen(NASDAQ:RGEN) develops products primarily in the areas ofAIDS, cancer and inflammation.
Cambridge NeuroScience Inc. of Cambridge, Mass., hasappointed William F. Holt, Ph.D., director of in vivopharmacology and Marvin B. Hendricks, Ph.D., head of the geneexpression group. Holt had been manager of metabolic diseasesat Pfizer Inc. Hendricks was at Repligen Corp., where he led thegroup responsible for mammalian cell expression. CambridgeNeuroScience (NASDAQ:CNSI) is developing treatments forsevere neurological and psychiatric disorders.
(c) 1997 American Health Consultants. All rights reserved.